Insights Into Axsome Therapeutics Inc (AXSM) Exposure By Institutions

After Hours

There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Earlier, Yahoo Finance discussed this stock as it revealed Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Stocks Info

As a NASDAQ listed company, AXSM falls under the Healthcare sector while operating within the Biotechnology industry segment. At the end of the last regular session, the stock closed at $96.89 and fluctuated between $97.66 as its day high and $95.78 as its day low. The current market capitalization of Axsome Therapeutics Inc is $4.58B. A total of 0.57 million shares were traded on the day, compared to an average of 0.87 shares.

Aside from predicting where a stock will go, investors also consider insider trades as an indicator of the stock’s future direction. During the recent three months, AXSM has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 1 BUYs and 2 SELLs from insiders. Insiders purchased 11,016 shares during that period but sold 29,588.

In the most recent transaction, Coleman Mark sold 18,572 shares of AXSM for 75.18 per share on Sep 15. After the transaction, the Director now owns 403,856 company shares. In a previous transaction on Sep 15, Coleman Mark sold 11,016 shares at 75.19 per share. AXSM shares that Director owns now total 25,097.

In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. According to analysts who have offered 12-month price targets for AXSM in the last 3 months, the mean price target is $119.40 with high estimates of $180.00 and low estimates of $90.00. In terms of 52-week highs and lows, AXSM has a high of $96.53 and a low of $53.71.

As of this writing, AXSM has an earnings estimate of $Avino Silver & Gold Mines Ltd. per share for the current quarter. EPS was calculated based on a consensus of Axsome Therapeutics, Inc. estimates, with a high estimate of $AXIM BIOTECHNOLOGIES INC per share and a lower estimate of $Axis Capital Holdings Limited.

Balance Sheet Annually/Quarterly

The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. AXSM’s latest balance sheet shows that the firm has $86.47M in Cash & Short Term Investments as of fiscal 2021. There were $49.71M in debt and $23.07M in liabilities at the time. Its Book Value Per Share was $5.70, while its Total Shareholder’s Equity was $15.63M.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for AXSM is Buy with a score of 4.67.

Most Popular

Related Posts